Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease

Arthritis and Rheumatism

Volumn 58, Issue 3, 2008, Pages 854-863

  Lau, Andrew C ^a   Duong, Trang T ^a   Ito, Shinya ^a   Yeung, Rae S M ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ELASTIN; GELATINASE B; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERITIS; ARTERY INJURY; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORONARY ARTERY ANEURYSM; ENZYME ACTIVITY; ENZYME ASSAY; IMMUNOBLOTTING; MOUSE; MUCOCUTANEOUS LYMPH NODE SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ZYMOGRAPHY;

ANIMALS; APOPTOSIS; BACTERIAL PROTEINS; CORONARY ARTERY DISEASE; CORONARY VESSELS; DISEASE MODELS, ANIMAL; ELASTICITY; ELASTIN; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LACTOBACILLUS CASEI; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOCUTANEOUS LYMPH NODE SYNDROME; MUSCLE, SMOOTH, VASCULAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 40549117462     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23225     Document Type: Article

References (40)

1. Taubert KA, Rowley AH, Shulman ST. Seven-year national survey of Kawasaki disease and acute rheumatic fever. Pediatr Infect Dis J 1994;13:704-8.
2. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Jpn J Allergol 1967;16:178-222. In Japanese.
3. Kawasaki T. Clinical signs and symptoms of mucocutaneous lymph node syndrome (Kawasaki disease). Jpn J Med Sci Biol 1979;32:237-8.
4. Barron KS, Shulman ST, Rowley A, Taubert K, Myones BL, Meissner HC, et al. Report of the National Institutes of Health Workshop on Kawasaki Disease. J Rheumatol 1999;26:170-90.
5. Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71.
6. Newburger JW, Takahashi M, Burns JC, Beiser AS, Chung KJ, Duffy CE, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986;315:341-7.
7. Kato H, Sugimura T, Akagi T, Sato N, Hashino K, Maeno Y, et al. Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85.
8. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80.
9. De Zorzi A, Colan SD, Gauvrcau K, Baker AL, Sundel RP, Newburger JW. Coronary artery dimensions may be misclassified as normal in Kawasaki disease. J Pediatr 1998;133:254-8.
10. Krettek A, Sukhova GK, Libby P. Elastogenesis in human arterial disease: a role for macrophages in disordered elastin synthesis. Arterioscler Thromb Vasc Biol 2003;23:582-7.
11. Curci JA, Liao S, Huffman MD, Shapiro SD, Thompson RW. Expression and localization of macrophage elastase (matrix metalloproteinase-12) in abdominal aortic aneurysms. J Clin Invest 1998;102:1900-10.
12. Zhang J, Schmidt J, Ryschich E, Schumacher H, Allenberg JR. Increased apoptosis and decreased density of medial smooth muscle cells in human abdominal aortic aneurysms. Chin Med J (Engl) 2003;116:1549-52.
13. Lopez-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA, Thompson RW. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol 1997;150:993-1007.
14. Henderson EL, Geng YJ, Sukhova GK, Whittemore AD, Knox J, Libby P. Death of smooth muscle cells and expression of mediators of apoptosis by T lymphocytes in human abdominal aortic aneurysms. Circulation 1999;99:96-104.
15. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP, et al. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms: an elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995;96:318-26.
16. Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, et al. Targeted gene disruption of matrix metalloprotcinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000;105:1641-9.
17. Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002;110:625-32.
18. Buckmaster MJ, Curci JA, Murray PR, Liao S, Allen BT, Sicard GA, et al. Source of elastin-degrading enzymes in mycotic aortic aneurysms: bacteria or host inflammatory response? Cardiovasc Surg 1999;7:16-26.
19. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-62.
20. Moon SK, Cha BY, Kim CH. ERK1/2 mediates TNF-α-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-κB and AP-1: involvement of the ras dependent pathway. J Cell Physiol 2004;198:417-27.
21. Siwik DA, Chang DL, Colucci WS. Interleukin-1β and tumor necrosis factor-α decrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro. Circ Res 2000;86:1259-65.
22. Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 2001;125:340-4.
23. Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 2001;104:860-3.
24. Chua PK, Melish ME, Yu Q, Yanagihara R, Yamamoto KS, Nerurkar VR. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease. Clin Diagn Lab Immunol 2003;10:308-14.
25. Lau AC, Rosenberg H, Duong TT, McCrindle BW, Yeung RS. Elastolytic matrix metalloproteinases and coronary outcome in children with Kawasaki disease. Pediatr Res 2007;61:710-5.
26. Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 2003;23:576-81.
27. Duong TT, Silverman ED, Bissessar MV, Yeung RS. Superantigenic activity is responsible for induction of coronary arteritis in mice: an animal model of Kawasaki disease. Int Immunol 2003;15:79-89.
28. Lehman TJ, Walker SM, Mahnovski V, McCurdy D. Coronary arteritis in mice following the systemic injection of group B Lactobacillus casei cell walls in aqueous suspension. Arthritis Rheum 1985;28:652-9.
29. Lehman TJ, Warren R, Gietl D, Mahnovski V, Prescott M. Variable expression of Lactobacillus casei cell wall-induced artertis: an animal model of Kawasaki's disease in selected inbred mouse strains. Clin Immunol Immunopathol 1988;48:108-18.
30. Chan WC, Duong TT, Yeung RS. Presence of IFN-γ does not indicate its necessity for induction of coronary arteritis in an animal model of Kawasaki disease. J Immunol 2004;173:3492-503.
31. Dubois M, Gilles KA, Hamilton JK, Rebers PA, Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem 1958;28:350-6.
32. 2+ ATPase-4 in the vascular smooth muscle cell cycle. Am J Physiol Cell Physiol 2003;285:C88-95.
33. Hui-Yuen JS, Duong TT, Yeung RS. TNF-α is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006;176:6294-301.
34. Rosenkranz ME, Schulte DJ, Agle LM, Wong MH, Zhang W, Ivashkiv L, et al. TLR2 and MyD88 contribute to Lactobacillus casei extract-induced focal coronary arteritis in a mouse model of Kawasaki disease. Circulation 2005;112:2966-73.
35. Ma Z, Qin H, Benveniste EN. Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-γ and IFN-β: critical role of STAT-1α. J Immunol 2001;167:5150-9.
36. Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-γ, tumor necrosis factor-α, and interleukin-1β. Arterioscler Thromb Vasc Biol 1996;16:19-27.
37. Satoh H, Nakamura M, Satoh M, Nakajima T, Izumoto H, Maesawa C, et al. Expression and localization of tumour necrosis factor-α and its converting enzyme in human abdominal aortic aneurysm. Clin Sci (Lond) 2004;106:301-6.
38. Niemann-Jonsson A, Ares MP, Yan ZQ, Bu DX, Fredrikson GN, Branen L, et al. Increased rate of apoptosis in intimal arterial smooth muscle cells through endogenous activation of TNF receptors. Arterioscler Thromb Vasc Biol 2001;21:1909-14.
39. Gearing AJ, Beckett P, Christodoulou M, Churchill M, Clements JM, Crimmin M, et al. Matrix metalloproteinases and processing of pro-TNF-α. J Leukoc Biol 1995;57:774-7.
40. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997;74:111-22.